Why the study?
Much remains unknown regarding acute flaccid myelitis pathogenesis and strategies for developing therapeutics or preventive modalities, including vaccines.
Summarizes scientific opportunities and priorities for future research on acute flaccid myelitis and associated enteroviruses based on an NIAID workshop.
AFM pathogenesis and optimal strategies remain incompletely defined; leaves open key questions for future research and clinical guidance.
Since 2014, cases of acute flaccid myelitis (AFM) have been reported in the United States in increasing numbers biennially, occurring in the late summer and early fall. Although there is unlikely to be a single causative agent of this syndrome, non-polio enteroviruses, including enterovirus D-68 (EV-D68), have had epidemiological and laboratory associations with AFM. Much remains to be known about AFM and AFM-associated enteroviruses, including disease pathogenesis and the best strategies for development of therapeutics or preventive modalities including vaccines. To catalyze research that addresses these scientific and clinical gaps, the National Institute of Allergy and Infectious Diseases convened a workshop entitled "AFM Preparedness: Addressing EV-D68 and Other AFM-Associated Enteroviruses" on 19-20 February 2020.
No takes yet. Share an insight, caveat, or question.
Lerner et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: